Shengmai San to prevent heart damage from breast cancer therapy
Part of Heart & circulation, Injuries & trauma clinical trials.
This trial tests if a traditional Chinese medicine called Shengmai San can protect the heart during chemotherapy and targeted therapy for HER2-positive breast cancer. Patients take the supplement alongside standard treatment to see if it reduces the risk of heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HER2-positive breast cancer that has not spread to other parts of the body (stage I–III).
- You plan to receive a specific type of chemo that includes doxorubicin or epirubicin, followed by trastuzumab with or without pertuzumab.
- Your heart function (LVEF) must be at least 50% before starting the anthracycline chemo.
- You must be in good enough health to carry out daily activities (ECOG score 0 or 1).
- You cannot have serious heart conditions like uncontrolled arrhythmia or heart failure (NYHA class II or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether grape polyphenols can help protect the heart in women being treated for breast cancer with certain chemotherapy drugs that can harm the heart. If you are at high risk for heart problems from chemo, this study may offer a way to reduce that risk.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
This trial tests whether a Chinese herbal medicine (Shenbailing granules) can help improve energy and blood health in women recovering from breast cancer surgery.
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
This trial tests whether a nutritional supplement called sulforaphane (SFN) can help protect heart function in people with breast cancer who are receiving doxorubicin (a chemotherapy that can affect the heart). Participants take caplets and have heart and safety monitoring to see if the supplement reduces heart-related side effects.
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
Hear when a new Cardiotoxicity Induced by Drug Therapy for Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.